Modifications of oxido-reductase activities in adriamycin-resistant leukaemia K562 cells

Biochemical Pharmacology

Volumn 56, Issue 4, 1998, Pages 451-457

  Denis Gay, Michelle ^a   Petit, Jean Michel ^a   Mazat, Jean Pierre ^b   Ratinaud, Marie Hélène ^a  

^a UNIVERSITY OF LIMOGES   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Adriamycin; Cytochrome c oxidase; Mitochondria; Multidrug resistance; Respiratory chain; Succinate ubiquinol oxido reductase

Indexed keywords

CYTOCHROME; CYTOCHROME C OXIDASE; DOXORUBICIN; LACTIC ACID;

ANTIBIOTIC RESISTANCE; ARTICLE; CELL CULTURE; CELL DAMAGE; CELL STRAIN K 562; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRION; OXYGEN CONSUMPTION; PRIORITY JOURNAL;

EID: 0031722711     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00084-7     Document Type: Article

References (25)

1. Frederick C.A., Williams L.D., Ughetto G., Van der Marel G.A., Van Boom J.H., Rich A., Wang A.H.J. Structural comparison of anticancer drug-DNA complexes: Adriamycin and daunomycin. Biochemistry. 29:1990;2538-2549.
2. 3H]doxorubicin after i.v. administration in the mouse. J Pharmacol Exp Ther. 216:1981;55-61.
3. Adachi K., Fujiura Y., Mayumi F., Nozuhara A., Sugiu Y., Sakanashi T., Hidaka T., Toshima H. A deletion of mitochondrial DNA in murine doxorubicin-induced cardiotoxicity. Biochem Biophys Res Commun. 195:1993;945-951.
4. Papadopoulou L.C., Tsiftsoglou A.S. Mitochondrial cytochrome c oxidase as a target site for daunomycin in K-562 cells and heart tissue. Cancer Res. 53:1993;1072-1078.
5. Demant E.J.F. Inactivation of cytochrome c oxidase activity in mitochondrial membranes during redox cycling of doxorubicin. Biochem Pharmacol. 41:1991;543-552.
6. Singal P.K., Deally C.M.R., Weinberg L.E. Subcellular effects of adriamycin in the heart. A concise review. J Mol Cell Cardiol. 19:1987;817-828.
7. Gottesman M.M., Pastan I. Resistance to multiple chemotherapeutic agents in human cancer cells. Trends Pharmacol Sci. 9:1988;54-58.
8. Helbig R., Gerland E., Speit G. The molecular nature of mutations induced by adriamycin at the hprt locus of V79 cells. Mutagenesis. 9:1994;113-116.
9. Endicott J.A., Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann Rev Biochem. 58:1989;137-171.
10. Yeh G.C., Occhipinti S.J., Cowan K.H., Chabner B.A., Myers C.E. Adriamycin resistance in human tumor cells associated with marked alterations in the regulation of the hexose monophosphate shunt and its response to oxidant stress. Cancer Res. 47:1987;5994-5998.
11. Lyon R.C., Cohen J.S., Faustino P.J., Megnin F., Myers C.E. Glucose metabolism in drug-sensitive and drug-resistant human breast cancer cells monitored by magnetic resonance spectroscopy. Cancer Res. 48:1988;870-877.
12. 31P nuclear magnetic resonance characterization and 2-deoxyglucose toxicity. Cancer Res. 51:1991;1638-1644.
13. Rustin P., Chrétien D., Bourgeron B., Gérard B., Rötig A., Saudubray J.M., Munnich A. Biochemical and molecular investigations in respiratory chain deficiencies. Clinica Chimica Acta. 228:1994;35-51.
14. Rickwood D., Wilson M.T., Darley-Usmar V.M. Isolation and characteristics of intact mitochondria. Darley-Usmar V.M., Rickwood D., Wilson M.T. Mitochondria A Practical Approach . 1987;1-16 IRL Press, Oxford.
15. Gornall A.G., Bardawill C.J., David M.M. Determinations of serum proteins by means of biuret reaction. J Biol Chem. 177:1949;751-766.
16. Ferguson L.R., Baguley B.C. Multidrug resistance and mutagenesis. Mutation Res. 285:1993;79-80.
17. Ellis C.N., Ellis M.B., Blakemore W.S. Effect of adriamycin on heart mitochondrial DNA. Biochem J. 245:1987;309-312.
18. Robinson B.H., Glerum D.M., Chow W., Petrova-Benedict R., Lightowlers R., Capaldi R. The use of skin fibroblast cultures in the detection of respiratory chain defects in patients with lacticacidemia. Pediatr Res. 28:1990;549-555.
19. Van den Bogert C., Spelbrink J.N., Dekkez H.L. Relationship between culture conditions and the dependency on mitochondrial function of mammalian cell proliferation. J Cell Physiol. 152:1992;632-638.
20. Letellier T., Malgat M., Mazat J.P. Control of oxidative phosphorylation in rat muscle mitochondria: Implications for mitochondrial myopathies. Biochim Biophys Acta. 1141:1993;58-64.
21. Letellier T., Heinrich R., Malgat M., Mazat J.P. The kinetic basis of threshold effects observed in mitochondrial diseases: A systemic approach. Biochem J. 302:1994;171-174.
22. Faillo M., Laigle A., Borrel M.N., Garnier-Suillerot A. Accumulation of degradation products of doxorubicin and pirarubicin formed in cell culture medium within sensitive and resistant cells. Biochem Pharmacol. 45:1993;659-665.
23. Goormaghtigh E., Brasseur R., Ruysschaert J.M. Adriamycin inactives cytochrome c oxidase by exclusion of the enzyme from its cardiolipin essential environment. Biochem Biophys Res Commun. 104:1982;314-320.
24. McPherson J.P., Brown G.A., Goldenberg G.J. Characterization of a DNA topoisomerase II alpha gene rearrangement in adriamycin-resistant P388 leukemia: Expression of a fusion messager RNA transcript encoding topoisomerase II alpha and the retinoic acid receptor alpha locus. Cancer Res. 53:1993;5885-5889.
25. Cutts S.M., Parsons P.G., Sturm R.A., Philipps D.R. Adriamycin-induced DNA adducts inhibit the DNA interactions of transcription factors and RNA polymerase. J Biol Chem. 271:1996;5422-5429.